Journal Guide

Expert Opinion on Drug Discovery ranks #176 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology * Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug * Perspectives on topical issues with potential impact on the future of drug discoveryThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Drug Safety ranks #100 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development. * Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies * Drug Safety Evaluations reviewing the safety data on a particular drug * Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse eventsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.Read More: http://informahealthcare.com/page/Description?journalCode=eds.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Orphan Drugs will be an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.

Expert Opinion on Therapeutic Patents ranks #3 of 13 in the Medicine, Legal category and #118 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. * Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area * Patent Evaluations examining the aims and chemical and biological claims of individual patents * Perspectives on issues relating to intellectual propertyThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D.

Expert Opinion on Therapeutic Targets ranks #53 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on recently identified novel molecular drug targets, providing expert opinion on the scope for future development and impact on drug discovery.The Editors welcome: * Reviews covering novel disease targets at the molecular level and their implications on future drug development * Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugsThe audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D.Read More: http://informahealthcare.com/page/Description?journalCode=ett.

Expert Review of Anti-infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of anti-infective research or clinical practice. This comprehensive coverage is augmented by:Expert Commentary- a personal view on the most effective or promising strategiesFive-year view - a clear perspective of future prospects within a realistic timescaleKey issues - an executive summary cutting to the author's most critical points.

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Through recent research advances we are increasingly able to understand and address immune-mediated diseases. Biotechnology is yielding success in areas with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis. Nevertheless, the burden of immune-mediated diseases is still enormous, with direct and indirect costs associated with such conditions believed to exceed $100 billion in the USA alone.Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.

Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.

Expert Review of Medical Devices (ISSN 1743-4440) provides commentary, analysis and debate for all professionals involved in research, development, testing and clinical use of devices.The journal serves the device research community by providing a comprehensive body of high-quality information from leading experts, all subject to rigorous peer-review. The Expert Review format is specially structured to optimize the value of the information to reader. Comprehensive coverage by each author in a key area of research or clinical practice is augmented by the following sections:* Expert Commentary - the author's personal assessment of the most promising therapies or strategies* Five-year view - the author is challenged to predict how the particular field will evolve in the medium term* Key issues - an executive summary of the author's most important points and conclusionsIn addition to the Review program, each issue also features Medical Device Profiles - objective assessments of specific devices in development or clinical use to help inform clinical practice. There are also Perspectives - overviews highlighting areas of current debate and controversy, together with reports from the conference scene and invited Editorials.

Expert Review of Molecular Diagnostics publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; cutting-edge editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations reviewing significant, recently published articles carefully selected and assessed by specialists in molecular diagnostic therapy.